Heart of the Mediterranean: Olive Oil and Cardiovascular Health

The Trial That Changed Dietary Science

In June 2013, the New England Journal of Medicine published the results of the PREDIMED trial — Prevención con Dieta Mediterránea — and the nutritional science community sat up straight. The study was large (7,447 participants), long (a median of nearly five years), and rigorous. It was also stopped early, a decision that clinical trialists make only when interim analysis shows a benefit so clear that it would be unethical to continue denying the intervention to the control group.

Participants at high cardiovascular risk were randomized to one of three diets: a Mediterranean diet supplemented with extra virgin olive oil (around four tablespoons per day), a Mediterranean diet supplemented with mixed nuts, or advice to follow a low-fat diet as a control. The primary endpoint was major cardiovascular events — heart attack, stroke, or cardiovascular death.

The result: the EVOO group showed a 30% relative reduction in major cardiovascular events compared to the low-fat control group. The nuts group showed a similar magnitude of benefit. Both Mediterranean diet groups outperformed low-fat advice by a margin that was not close.

The 30% reduction was achieved not through a pharmaceutical intervention, but through the consistent use of a specific food — extra virgin olive oil — as the primary dietary fat. No drug company funded this finding.

Oleic Acid and the Lipid Profile

Olive oil is approximately 73% oleic acid, a monounsaturated fatty acid. Understanding what oleic acid does in the body is essential to understanding one part — though not all — of olive oil's cardiovascular story.

When oleic acid replaces saturated fatty acids in the diet, multiple things happen to the blood lipid profile. LDL cholesterol — the lipoprotein associated with atherosclerotic plaque when oxidized — tends to decrease modestly. More importantly, the character of LDL changes: a higher oleic acid intake is associated with the production of larger, less dense LDL particles, which are less prone to becoming embedded in arterial walls than the small, dense LDL particles associated with high saturated fat intake.

HDL cholesterol — sometimes called good cholesterol for its role in reverse cholesterol transport — tends to be maintained or slightly increased. The overall ratio of total cholesterol to HDL improves, which is a more predictive cardiovascular marker than total cholesterol alone.

Oleic acid also appears to reduce the expression of cell adhesion molecules on the endothelial surface — the interior lining of blood vessels — which are part of the mechanism by which LDL infiltrates the arterial wall to begin plaque formation. Less adhesion means less infiltration.

Polyphenols and Oxidative Stress: The Larger Story

As important as oleic acid is, the case for olive oil's cardiovascular superiority over other high-oleic oils — such as high-oleic sunflower or canola — rests substantially on its polyphenol content. Refined olive oil, which shares a similar fatty acid profile to EVOO but has been deodorized and stripped of its phenolics, does not show the same effects.

The specific cardiovascular mechanisms of olive oil polyphenols operate at several levels.

Oxidized LDL is a key step in atherosclerosis — the disease process underlying most heart attacks. LDL in the bloodstream becomes pro-atherogenic primarily when it is oxidized by free radicals. Hydroxytyrosol and related polyphenols are among the most potent inhibitors of LDL oxidation identified in food, and the EU has formally approved a health claim based on this effect.

Endothelial function — the ability of blood vessels to dilate in response to increased flow — is an important early marker of cardiovascular risk. Studies have shown that EVOO consumption improves endothelial function through polyphenol-mediated upregulation of nitric oxide synthase, the enzyme that produces the vasodilating molecule nitric oxide. Better endothelial function means more responsive, flexible arteries.

Platelet aggregation — the tendency of blood cells to clump, which is the immediate trigger of most heart attacks — is reduced by oleocanthal and other polyphenols through mechanisms that include COX-1 inhibition, the same pathway targeted by aspirin. Low-dose aspirin has been widely used for exactly this effect; olive oil polyphenols appear to operate on an overlapping mechanism at gentler, continuous concentrations.

Blood pressure shows modest but consistent improvement with regular EVOO consumption in clinical studies. A meta-analysis of multiple trials found that high olive oil intake was associated with reductions of approximately 3 mmHg in systolic and 2 mmHg in diastolic pressure — small numbers at the individual level, but meaningful at the population level as risk reduction.

Half a Tablespoon a Day: Where the Threshold Is

One of the practical questions that follows from this evidence is: how much do you need? The PREDIMED trial used around 50 grams per day — roughly four tablespoons — which is culturally normal in Andalusia and Crete but feels like a lot to someone accustomed to using oil sparingly.

More recent analyses suggest that meaningful cardiovascular effects begin at much lower consumption levels. A 2022 study in the Journal of the American College of Cardiology found that replacing just 10 grams per day of margarine, butter, mayonnaise, or other fats with olive oil was associated with a significantly reduced risk of cardiovascular and cancer mortality. Another analysis found measurable HDL benefits at just 20 grams per day — under two tablespoons.

The dose-response relationship appears to be real but not strictly linear: benefits begin at modest consumption and grow with increased intake, up to the amounts seen in traditional Mediterranean populations. This is genuinely encouraging news — you do not need to douse everything in oil to receive meaningful cardiovascular support. But the quality of those grams matters enormously.

EVOO vs. Refined Olive Oil: The Phenolic Difference

Not all olive oil sold as olive oil carries the same cardiovascular benefit. Refined olive oil — labeled "Pure Olive Oil," "Light Olive Oil," or simply "Olive Oil" — has been subjected to industrial deodorization and bleaching that strips nearly all of its polyphenols. It retains a similar fatty acid profile to EVOO, but the protective molecules that drive many of the cardiovascular mechanisms are gone.

This distinction is clinically significant. A Spanish study directly comparing EVOO to refined olive oil in a crossover design found that EVOO showed superior effects on endothelial function, oxidized LDL, and several inflammatory markers. The oleic acid content was essentially identical between groups; the polyphenol content was not. The difference in outcome confirmed that it is the combination of monounsaturated fat and bioactive polyphenols — not fatty acid composition alone — that makes high-quality extra virgin olive oil what it is for cardiovascular health.

The takeaway is simple but consequential: for cardiovascular benefit, the label matters. Extra virgin is not a premium tier for food enthusiasts alone — it is the category that carries the specific compounds responsible for the effects documented in decades of research. Using refined or blended olive oils as a substitute is not equivalent, and the evidence is clear enough that the distinction deserves to be taken seriously.